MX2022012957A - Metodos de uso de inhibidores de la quinasa rho para tratar la enfermedad de alzheimer. - Google Patents

Metodos de uso de inhibidores de la quinasa rho para tratar la enfermedad de alzheimer.

Info

Publication number
MX2022012957A
MX2022012957A MX2022012957A MX2022012957A MX2022012957A MX 2022012957 A MX2022012957 A MX 2022012957A MX 2022012957 A MX2022012957 A MX 2022012957A MX 2022012957 A MX2022012957 A MX 2022012957A MX 2022012957 A MX2022012957 A MX 2022012957A
Authority
MX
Mexico
Prior art keywords
methods
rho kinase
preferred
disease
kinase inhibitors
Prior art date
Application number
MX2022012957A
Other languages
English (en)
Spanish (es)
Inventor
Sven Jacobson
Thomas Macallister
Original Assignee
Woolsey Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Woolsey Pharmaceuticals Inc filed Critical Woolsey Pharmaceuticals Inc
Publication of MX2022012957A publication Critical patent/MX2022012957A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
MX2022012957A 2020-04-23 2021-01-08 Metodos de uso de inhibidores de la quinasa rho para tratar la enfermedad de alzheimer. MX2022012957A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063014272P 2020-04-23 2020-04-23
PCT/US2021/012588 WO2021216139A1 (en) 2020-04-23 2021-01-08 Methods of using rho kinase inhibitors to treat alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2022012957A true MX2022012957A (es) 2022-11-09

Family

ID=78269840

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012957A MX2022012957A (es) 2020-04-23 2021-01-08 Metodos de uso de inhibidores de la quinasa rho para tratar la enfermedad de alzheimer.

Country Status (7)

Country Link
US (3) US12329761B2 (cg-RX-API-DMAC7.html)
EP (1) EP4138842A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023523706A (cg-RX-API-DMAC7.html)
CN (1) CN115996728A (cg-RX-API-DMAC7.html)
CA (1) CA3175183A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022012957A (cg-RX-API-DMAC7.html)
WO (1) WO2021216139A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11642352B2 (en) * 2020-03-25 2023-05-09 Woolsey Pharmaceuticals, Inc. Methods of treating wandering in Lewy dody dementia
US12329761B2 (en) * 2020-04-23 2025-06-17 Woolsey Pharmaceuticals, Inc. Methods of using rho kinase inhibitors to treat alzheimer's disease
WO2023097151A1 (en) 2021-11-29 2023-06-01 Woolsey Pharmaceuticals, Inc. Methods of treating agitation and other dementia-associated behavioral symptoms
CN115998736B (zh) * 2023-03-28 2023-06-23 中国人民解放军军事科学院军事医学研究院 Y-27632在特异性抑制幻觉作用中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117896A1 (de) 2004-06-03 2005-12-15 Schering Aktiengesellschaft Formulierungen, die fasudil, eine matrix und einem mantel enthalten
US20060212090A1 (en) * 2005-03-01 2006-09-21 Functional Neuroscience Inc. Method of treating cognitive disorders using neuromodulation
EP2061314A4 (en) * 2006-08-10 2010-08-04 Translational Genomics Res Inst CONNECTIONS TO IMPROVE LEARNING AND MEMORY
US20110237600A1 (en) * 2008-05-12 2011-09-29 Amnestix, Inc. Compounds for improving learning and memory
US20120010196A1 (en) * 2010-04-02 2012-01-12 Qin Quingyu Methods of treating neurodegenerative disorders and diseases
EP2825175B1 (en) * 2012-03-12 2017-07-26 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Rho kinase inhibitors for use in treating amyotrophic lateral sclerosis
WO2017003466A1 (en) * 2015-06-30 2017-01-05 University Of South Florida Conversion of non-neuronal cells into neurons
WO2021142183A1 (en) * 2020-01-09 2021-07-15 Woolsey Pharmaceuticals, Inc Methods of treating cortical dementia associated wandering
US11642352B2 (en) 2020-03-25 2023-05-09 Woolsey Pharmaceuticals, Inc. Methods of treating wandering in Lewy dody dementia
US12329761B2 (en) * 2020-04-23 2025-06-17 Woolsey Pharmaceuticals, Inc. Methods of using rho kinase inhibitors to treat alzheimer's disease
US11311553B1 (en) 2020-10-22 2022-04-26 Woolsey Pharmaceuticals, Inc. Methods of treating 4-repeat tauopathies
WO2023097151A1 (en) * 2021-11-29 2023-06-01 Woolsey Pharmaceuticals, Inc. Methods of treating agitation and other dementia-associated behavioral symptoms

Also Published As

Publication number Publication date
US20230302011A1 (en) 2023-09-28
EP4138842A1 (en) 2023-03-01
CA3175183A1 (en) 2021-10-28
US20230190765A1 (en) 2023-06-22
CN115996728A (zh) 2023-04-21
EP4138842A4 (en) 2024-04-24
JP2026053635A (ja) 2026-03-25
US12329761B2 (en) 2025-06-17
JP2023523706A (ja) 2023-06-07
US11771704B1 (en) 2023-10-03
US20250268911A1 (en) 2025-08-28
WO2021216139A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
MX2022015800A (es) Metodos de uso de inhibidores de la quinasa rho para tratar demencia vascular.
MX2025012306A (es) Inhibidores del gen de sarcoma de rata de kirsten (kras) de 2-azabiciclo [2.2.1] heptano
PH12022552739A1 (en) Fused tricyclic kras inhibitors
CR20240059A (es) Compuestos tricíclicos como inhibidores de kras.
Schlesinger et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study
MX2024004444A (es) Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras).
ZA202109010B (en) Compounds and methods for the treatment of covid-19
MXPA05003550A (es) Incremento de dosificacion y dosis diaria dividida de anti-depresivos para tratar padecimientos neurologicos.
MX2025005941A (es) Moduladores de la actividad tnf-\03b1
SI1456380T1 (sl) Smad inhibitorji za zdravljenje cns bolezni
MX2024000237A (es) Arnip que inhibe la expresión del gen angptl3 y uso del mismo.
MX2025014320A (es) Compuestos nitrogenados aromaticos, metodos de preparacion y usos medicinales
MA69153A1 (fr) Méthodes de traitement d'une splénomégalie
JP2023523706A5 (cg-RX-API-DMAC7.html)
MX2022012310A (es) Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton.
UY39673A (es) Pauta posológica de sotorasib
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
Tadros et al. Anxiety disorders, PTSD and OCD: systematic review of approved psychiatric medications (2008–2024) and pipeline phase III medications
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
MX2023007150A (es) Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.
CN109069466A (zh) 5-ht6受体拮抗剂用于治疗阿尔茨海默病伴情感淡漠共病
Nash et al. SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
MX2020007941A (es) Metodo para prevenir o tratar enfermedad de alzheimer.
Segamarchi et al. Would it be recommended treating multiple sclerosis relapses with high dose oral instead intravenous steroids during the COVID-19 pandemic? Yes
MX2022010513A (es) Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton.